Inhibikase Therapeuticsinc Stock Number Of Shares Shorted
| IKT Stock | USD 1.72 0.27 13.57% |
Inhibikase TherapeuticsInc fundamentals help investors to digest information that contributes to Inhibikase TherapeuticsInc's financial success or failures. It also enables traders to predict the movement of Inhibikase Stock. The fundamental analysis module provides a way to measure Inhibikase TherapeuticsInc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inhibikase TherapeuticsInc stock.
Inhibikase | Number Of Shares Shorted |
Inhibikase TherapeuticsInc Company Number Of Shares Shorted Analysis
Inhibikase TherapeuticsInc's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Inhibikase TherapeuticsInc Number Of Shares Shorted | 135.25 K |
Most of Inhibikase TherapeuticsInc's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inhibikase TherapeuticsInc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Inhibikase Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Inhibikase TherapeuticsInc is extremely important. It helps to project a fair market value of Inhibikase Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Inhibikase TherapeuticsInc's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inhibikase TherapeuticsInc's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inhibikase TherapeuticsInc's interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Inhibikase TherapeuticsInc has 135.25 K of outstending shares currently sold short by investors. This is 95.77% lower than that of the Biotechnology sector and 97.35% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 97.13% higher than that of the company.
Inhibikase Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inhibikase TherapeuticsInc's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inhibikase TherapeuticsInc could also be used in its relative valuation, which is a method of valuing Inhibikase TherapeuticsInc by comparing valuation metrics of similar companies.Inhibikase TherapeuticsInc is currently under evaluation in number of shares shorted category among related companies.
Inhibikase TherapeuticsInc Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inhibikase TherapeuticsInc from analyzing Inhibikase TherapeuticsInc's financial statements. These drivers represent accounts that assess Inhibikase TherapeuticsInc's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inhibikase TherapeuticsInc's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 102.2M | 69.4M | 26.8M | 6.8M | 7.8M | 7.4M | |
| Enterprise Value | 102.5M | 55.7M | (13.7M) | (1.8M) | (2.0M) | (1.9M) |
Inhibikase Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.64 | ||||
| Current Valuation | (2.66 M) | ||||
| Shares Outstanding | 6.48 M | ||||
| Shares Owned By Insiders | 13.85 % | ||||
| Shares Owned By Institutions | 9.20 % | ||||
| Number Of Shares Shorted | 135.25 K | ||||
| Price To Book | 1.31 X | ||||
| Price To Sales | 55.21 X | ||||
| Revenue | 260.5 K | ||||
| Gross Profit | (8.26 M) | ||||
| EBITDA | (19.91 M) | ||||
| Net Income | (19.03 M) | ||||
| Cash And Equivalents | 32.21 M | ||||
| Cash Per Share | 1.28 X | ||||
| Total Debt | 622 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.56 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | (18.09 M) | ||||
| Short Ratio | 2.35 X | ||||
| Earnings Per Share | (3.57) X | ||||
| Target Price | 17.5 | ||||
| Beta | 1.32 | ||||
| Market Capitalization | 9.97 M | ||||
| Total Asset | 14.51 M | ||||
| Retained Earnings | (66.9 M) | ||||
| Working Capital | 10.77 M | ||||
| Net Asset | 14.51 M |
About Inhibikase TherapeuticsInc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibikase TherapeuticsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibikase TherapeuticsInc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibikase TherapeuticsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inhibikase TherapeuticsInc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inhibikase TherapeuticsInc's short interest history, or implied volatility extrapolated from Inhibikase TherapeuticsInc options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Inhibikase TherapeuticsInc Piotroski F Score and Inhibikase TherapeuticsInc Altman Z Score analysis. For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase TherapeuticsInc guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Inhibikase Stock analysis
When running Inhibikase TherapeuticsInc's price analysis, check to measure Inhibikase TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase TherapeuticsInc is operating at the current time. Most of Inhibikase TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Inhibikase TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase TherapeuticsInc's price. Additionally, you may evaluate how the addition of Inhibikase TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Inhibikase TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibikase TherapeuticsInc. If investors know Inhibikase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibikase TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.57) | Revenue Per Share 0.049 | Quarterly Revenue Growth (1.00) | Return On Assets (0.64) | Return On Equity (1.19) |
The market value of Inhibikase TherapeuticsInc is measured differently than its book value, which is the value of Inhibikase that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibikase TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Inhibikase TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibikase TherapeuticsInc's market value can be influenced by many factors that don't directly affect Inhibikase TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibikase TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inhibikase TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibikase TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.